177 related articles for article (PubMed ID: 35759653)
21. A FluoroSpot B assay for the detection of IgA and IgG SARS-CoV-2 spike-specific memory B cells: Optimization and qualification for use in COVID-19 vaccine trials.
Bisceglia H; Barrier J; Ruiz J; Pagnon A
J Immunol Methods; 2023 Apr; 515():113457. PubMed ID: 36914088
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
23. Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2- Recovered Dialysis Patients.
Attias P; Azzaoui I; El Karoui K; de La Selle A; Sokal A; Chappert P; Grimbert P; Fernandez I; Bouvier M; Samson C; Dahmane D; Rieu P; Nizard P; Fourati S; Sakhi H; Mahévas M;
Clin J Am Soc Nephrol; 2022 Jul; 17(7):1008-1016. PubMed ID: 35764393
[TBL] [Abstract][Full Text] [Related]
24. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
25. Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination.
Casado JL; Vizcarra P; Martín-Hondarza A; Blasco M; Grandal-Platero M; Haemmerle J; Fernández-Escribano M; Vallejo A
Viruses; 2023 Feb; 15(3):. PubMed ID: 36992336
[TBL] [Abstract][Full Text] [Related]
26. BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2.
Brewer RC; Ramadoss NS; Lahey LJ; Jahanbani S; Robinson WH; Lanz TV
Nat Immunol; 2022 Jan; 23(1):33-39. PubMed ID: 34848871
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
Giuliano AR; Lancet JE; Pilon-Thomas S; Dong N; Jain AG; Tan E; Ball S; Tworoger SS; Siegel EM; Whiting J; Mo Q; Cubitt CL; Dukes CW; Hensel JA; Keenan RJ; Hwu P
JAMA Oncol; 2022 May; 8(5):748-754. PubMed ID: 35266953
[TBL] [Abstract][Full Text] [Related]
28. Persistent but atypical germinal center reaction among 3
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Chen Y; Meisel C; Jahrsdörfer B; Ludwig C; Schrezenmeier H; Lino AC; Dörner T
Front Immunol; 2022; 13():943476. PubMed ID: 36032111
[TBL] [Abstract][Full Text] [Related]
29. Detection of specific RBD
Del Pino Molina L; Bravo Gallego LY; Nozal P; Soto-Serrano Y; Martínez-Feito A; Reche-Yebra K; González-Torbay A; Cuesta-Martín de la Cámara R; Gianelli C; Cámara C; González-García J; González-Muñoz M; Rodríguez-Pena R; López Granados E
Front Immunol; 2023; 14():1136308. PubMed ID: 37215146
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
31. COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads.
Golan Y; Prahl M; Cassidy AG; Gay C; Wu AHB; Jigmeddagva U; Lin CY; Gonzalez VJ; Basilio E; Chidboy MA; Warrier L; Buarpung S; Li L; Murtha AP; Asiodu IV; Ahituv N; Flaherman VJ; Gaw SL
Front Immunol; 2021; 12():777103. PubMed ID: 34804068
[TBL] [Abstract][Full Text] [Related]
32. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
33. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
34. A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects.
Martinuzzi E; Benzaquen J; Guerin O; Leroy S; Simon T; Ilie M; Hofman V; Allegra M; Tanga V; Michel E; Boutros J; Maniel C; Sicard A; Glaichenhaus N; Czerkinsky C; Blancou P; Hofman P; Marquette CH
Clin Infect Dis; 2022 Dec; 75(12):2053-2059. PubMed ID: 35579991
[TBL] [Abstract][Full Text] [Related]
35. Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.
van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
J Clin Immunol; 2023 Aug; 43(6):1104-1117. PubMed ID: 37231290
[TBL] [Abstract][Full Text] [Related]
36. Germinal centre-driven maturation of B cell response to mRNA vaccination.
Kim W; Zhou JQ; Horvath SC; Schmitz AJ; Sturtz AJ; Lei T; Liu Z; Kalaidina E; Thapa M; Alsoussi WB; Haile A; Klebert MK; Suessen T; Parra-Rodriguez L; Mudd PA; Whelan SPJ; Middleton WD; Teefey SA; Pusic I; O'Halloran JA; Presti RM; Turner JS; Ellebedy AH
Nature; 2022 Apr; 604(7904):141-145. PubMed ID: 35168246
[TBL] [Abstract][Full Text] [Related]
37. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
[TBL] [Abstract][Full Text] [Related]
38. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
39. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine.
Sheng WH; Ieong SM; Lin PH; Hsieh MJ; Yang HC; Pan CF; Chao TL; Chang SY; Chang SC
J Formos Med Assoc; 2023 Feb; 122(2):121-131. PubMed ID: 36127206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
